Study Stopped
Protocol stopped for safety reason
rTMS and Body Shape Perception
STIMOREX
Effect of Transcranial Magnetic Stimulation on Disturbance of Body Shape Perception in Patients With Anorexia Nervosa
1 other identifier
interventional
22
1 country
1
Brief Summary
Anorexia nervosa (AN) is a frequent, potentially life-threatening eating disorder characterized by a resistance to maintaining body weight at or above a minimally normal weight for age and height, an intense fear of weight gain or being "fat" even though underweight, a loss of menstrual periods in girls and women post-puberty and a disturbance in the experience of body weight or shape. Body weight and shape dissatisfaction is linked to the development, maintenance and relapse of AN. Neuroimaging studies have shown that the inferior parietal cortex is involved in body image perception and less activated in patients with AN compared with healthy subjects. Repetitive transcranial magnetic stimulation (rTMS) is used to modulate cortical excitability, and particularly to increase excitability with high-frequency rTMS. The aim of this study was to investigate the effect of "excitatory" high-frequency rTMS over the "hypoactive" inferior parietal cortex of 54 patients with AN. This randomized, double-blind, placebo-controlled study will compare effective rTMS (2000 ten-Hz stimulations per session, applied at 90% of the resting motor threshold, with 10 sessions in two weeks) versus placebo rTMS. Assessments will be performed before rTMS and after the last rTMS session (immediately after, at 15 days and three months). The principal criteria for judgement is a body image satisfaction scale (Boby Shape Questionnaire, BSQ-34). The secondary criteria for judgement are eating behaviour scales (Eating Attitude Test, EAT-40; Bulimia test, BULIT and Eating Disorders Inventory, EDI-2), the Hamilton depression rating scale and Hamilton anxiety rating scale, a quality of life scale (Short-Form Health Survey, SF-36), a body composition analysis using a Dual-energy X-ray absorptiometry and the alpha-MSH autoantibodies levels (biomarker for eating disorders recently described). Inferior parietal cortex rTMS could not only improve body image perception, but also help in the treatment of eating disorders, allowing weight gain with a decreased anxiety and improving patients' quality of life. Also positive results could have direct therapeutic implications with the possibility to complete regular rTMS sessions, or to implant extradural electrodes for chronic parietal cortex stimulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2012
CompletedFirst Posted
Study publicly available on registry
October 30, 2012
CompletedStudy Start
First participant enrolled
May 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2017
CompletedMay 30, 2018
May 1, 2018
4.6 years
September 24, 2012
May 25, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
BSQ-34 scale (Body Shape Questionnaire)
Just after rTMS
Secondary Outcomes (11)
EAT-40 scale (eating attitude test)
Before rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMS
BULIT scale (bulimia test)
Before rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMS
EDI-2 scale (eating disorder inventory)
Before rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMS
Hamilton scale
Before rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMSBefore rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMS
Quality of Life Scale, MOS 36 Item Short-Form Health Survey or SF-36
Before rTMS, just after rTMS, 15 days after rTMS and 3 months after rTMS
- +6 more secondary outcomes
Study Arms (2)
Effective arm
ACTIVE COMPARATOREffective coil
Placebo arm
PLACEBO COMPARATORPlacebo coil
Interventions
Eligibility Criteria
You may qualify if:
- Female
- Age above 18
- Restrictive anorexia nervosa with a disease duration more than one year and less than three years.
- Body Mass Index below 16
- Patient receiving or having received optimal treatment for anorexia nervosa
- Right-handed
- Normal blood ionogramme
- Previous stable antidepressor treatment for one month and no expected modification in the three following months
- Patients arriving by car with someone else or by public transportation
You may not qualify if:
- Pregnancy
- Contraindication to transcranial magnetic stimulation i.e. pace-maker, cardiac valve protheses, metallic protheses etc.
- History of epileptic seizure
- Cerebral lesion of any etiology (post-traumatic, tumoral, vascular etc.)
- History of previous rTMS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rouen University Hospital
Rouen, 76031, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nathalie CHASTAN, MD
UH Rouen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2012
First Posted
October 30, 2012
Study Start
May 1, 2013
Primary Completion
December 15, 2017
Study Completion
December 15, 2017
Last Updated
May 30, 2018
Record last verified: 2018-05